Breast Cancer Clinical Trial
— BREHABOfficial title:
Prehabilitation and Rehabilitation in Breast Cancer Surgery Patients - a Pilot Study
Verified date | May 2024 |
Source | Franciscus Gasthuis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prehabilitation and rehabilitation through personalized lifestyle counseling in patients with breast cancer.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 1, 2024 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion criteria 1. Woman with a confirmed breast cancer diagnosis 2. Planned surgical treatment of breast cancer 3. Age 18 years or older 4. Provision of written informed consent Exclusion criteria 1. Severe mental retardation, which limits the ability to follow instructions independently 2. Severe psychiatric problems, which limits the ability to follow instructions independently 3. Legal incapacity 4. Language barrier: If we cannot find a lifestyle coach who speaks the patient's language, unfortunately we cannot offer the lifestyle coaching in its entirety, and this option will be omitted for the patient. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Franciscus Gasthuis en Vlietland | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Franciscus Gasthuis |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment/consent rate | To estimate patient recruitment/consent rate to the prehabilitation/rehabilitation group Enrolment logs will be recorded for all patients who meet the eligibility criteria. Reasons for non-participation will be recorded. We define a success criterion of 40% of the total number of participants invited to be recruited to the pilot study. | From baseline to 6 months postoperatively | |
Primary | Attendance rate | To estimate patient attendance, measured by the number of sessions attended out of 10. Reasons for non-attendance will be collected and withdrawals tracked. We will consider an attendance rate of 80% satisfactory | From baseline to 6 months postoperatively | |
Primary | Patient adherence | To estimate patient adherence monitored with the aid of the wearables. Adherence is defined as at least 150 min of moderate intensity exercise and at least two strength training sessions per week. Exercise instructions are based on the Health Council's exercise guidelines. We will consider an adherence of 70% as satisfactory. | From baseline to 6 months postoperatively | |
Primary | Withdrawals | To estimate the number of withdrawals, defined as the proportion of patients who quit the intervention before reaching the primary endpoint (HRQOL at six months after surgery). Information about the reasons for withdrawal will be collected. | From baseline to 6 months postoperatively | |
Primary | Patient satisfaction | To estimate patient satisfaction with the programme assessed during three interviews: at four weeks, at three months after surgery and at the end of the study. Satisfaction is defined as: satisfaction with the lifestyle coach, satisfaction with the duration of the intervention, satisfaction with the physical training programme. Patients will be given room for their own input to improve the intervention. | From baseline to 6 months postoperatively | |
Primary | Selection bias | To explore any evidence of selection bias in participants recruited into the study (assessed through participant characteristics at baseline). | From baseline to 6 months postoperatively | |
Secondary | Likely changes in Health Related Quality of Life (HRQOL) | To investigate likely changes in the primary outcome measure HRQOL measured with the EORTC-QLQ-30 questionnaire at six months after surgery. | Baseline, the day before surgery, 6 months postoperatively | |
Secondary | Likely changes in BMI | Body Mass Index | Baseline, the day before surgery, 6 months postoperatively | |
Secondary | Likely changes in functional capacity (physical fitness) | Measured using the 6 minute walking test (6MWT) | Baseline, the day before surgery, 6 months postoperatively | |
Secondary | Likely changes in the number of postoperative complications | Complications within 30 days after surgery, measured with the Comprehensive Complication Index (CCI) | 30 days after surgery | |
Secondary | Likely changes in smoking status | Smoking status (yes/no) as assessed by the primary investigator | Measured at baseline and 6 months postoperatively | |
Secondary | Likely changes in postoperative functional recovery | Measured the day after surgery with the MILAS and DEMMI questionnaires | The day after surgery | |
Secondary | Likely changes in mean score of the different BREAST-Q scales | Measured using the BREAST-Q questionnaire | The questionnaire will be administered at enrolment and at six months after surgery. | |
Secondary | Likely changes in mean score of quality of life by means of the EORTC-BR23 questionnaire | Measured using the EORTC-BR23 questionnaire | The questionnaire will be administered at enrolment and at six months after surgery. | |
Secondary | Likely changes in mean score of the different EORTC-QLQ-30 scales which will be administered at enrolment and six months after surgery. | Measured using the EORTC-QLQ-30 questionnaire | The questionnaire will be administered at enrolment and at six months after surgery. | |
Secondary | Likely changes in mean score of the EQ5D-5L questionnaire | Measured using the EQ-5D-5L questionnaire | The questionnaire will be administered at enrolment and at six months after surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |